A Study to Investigate Efficacy and Safety of KBL697 in Patients with Moderate Plaque Type Psoriasis

A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of KBL697 in Patients with Moderate Plaque Type Psoriasis

The study is designed to investigate efficacy and safety of KBL697 in patients with Moderate Plaque Type Psoriasis. KBL697 has been developed as a potential new treatment for Psoriatic Plaque.

Inclusion Criteria:

• Male or female, aged 18 to 75 years (inclusive)
• Have a diagnosis of plaque type psoriasis for ≥ 6 months
• Must have chronic plaque type psoriasis of moderate severity
• All subjects must agree and commit to the use of a reliable contraceptive regimen.

Exclusion Criteria:

• Current diagnosis of forms of psoriasis other than chronic plaque type only
• Drug-induced psoriasis
• Other inflammatory skin disease that may confound the evaluation of plaque psoriasis
• Failed 2 or more systemic treatments for plaque psoriasis
• Medicinal shampoos that contain tar and/or salicylic acid within 2 weeks prior to Baseline Visit